Kalqyl och FairValue presenterar nu en samlad genomgång av sex bolag i tidig tillväxtfas, noterade p...
Redeye provides updated estimates and a new fair value range for BONESUPPORT following the prelimina...
Duell reported Q1 net sales at EUR 25.0m, below our forecast of EUR 27.
Duell's fiscal year 2026 got off to a challenging start, as sales declined 12% y/y.
Redeye provides a quick comment on the trading update from Cheffelo, released this morning.
We refresh our investment case for Cereno Scientific as the company enters a key value inflection pe...
Ahead of Q4/25, we expect CDON group’s positive trend to continue and expect GMV growth of 12.
Ahead of Elanders' Q4 report, we lower 2025E adjusted EBITA by 2% and 2026E-27E by 6%, due to FX and...
Redeye revises its Base Case and estimates following an analyst change, retaining its positive view.
Redeye is positive about Optomed’s partnership with Aireen and the EU approval for AI integration wi...
Duell reports Q1 (Sep–Nov) on January 14. We expect a challenging quarter, with weak market conditio...
Redeye provides a preview ahead of Tradedoubler’s Q4 2025 report, scheduled for publication on 12 Fe...
At SEB's Nordic Seminar, Duni Group’s CEO Robert Dackeskog and CFO Magnus Carlsson outlined why 2026...
At SEB’s Nordic Seminar, Bactiguard’s CEO, Christine Lind, presented its technology and provided an ...
At SEB's Nordic Seminar, G5 Entertainment's CFO Stefan Wikstrand presented the G5 story, which over ...
Redeye is positive about Corline’s directed share issue and loan agreement with Kardium.
Endomines production in Q4 was weaker than expected, but further gold price momentum continues to ca...
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q4 2025 ended a...
Redeye lowers its forecasts and Base Case slightly, which, however, remains substantially above the ...
Redeye comments on the news that the TRANBERG Thermal Therapy System for focal laser ablation (FLA) ...
